This Chronic Pain Drug, Gabapentin, Could Increase Risk of Cognitive Decline

Pharmacology, drug science and how they affect our body, constantly evolves. It brings us new improved treatments for daily diseases while putting new light on the long -term effects of drugs used for decades.

Recent observation study published in Regional anesthesia and pain medication examined the potential disadvantages of gabapentine, a commonly prescribed medication for chronic pain. Researchers from the University School of Medicine of Cleveland and Arizona State University analyzed health data of more than 25,000 adults and found that the reception of six gabapentine prescriptions or more low back pain was correlated with a higher risk of developing a dementia or a light cognitive deficiency (MCI).

While the team stressed that a more in -depth investigation is necessary to establish a causal relationship, they stressed in a press release That their results “support the need for close monitoring of adult patients have prescribed gabapentine to assess the potential cognitive decline”.

What is GabaPentin medication?

Gabapentine has been used for more than 20 years, especially for nerve -related pain. Originally approved to treat partial crises, it works by binding to calcium tension channels in the brain, reducing the release of specific neurotransmitters and attenuating pain signals.

In 2016 only, 64 million Gabapentine prescriptions were distributed in the United States, which makes it the tenth most commonly prescribed drug. Its popularity comes in part from its relatively low addictive potential compared to opioids, and it was even considered as potentially neuroprotective in the treatment of neuropathic pain.

However, concerns are now emerging concerning the possible links with neurodegeneration. Until now, research has been mixed and there is no scientific consensus on the question of whether the use of gabapentine contributes to the cognitive decline of patients with chronic pain.

Find out more: Why does pain hurt?

The risk of dementia increases with the prescription frequency

To explore these questions, the researchers analyzed Trinetx data, a large health research network containing electronic health files of 68 health care organizations across states. They examined anonymized recordings of 26,414 adults diagnosed with chronic low back pain between 2004 and 2024, comparing those prescribed from Gabapentine to those who did not do so.

Their results indicated that adults prescribed gabapentine six times or more in the face of almost a third higher risk of dementia and were almost twice as likely to undergo a slight cognitive impairment within 10 years of the first exposure of low back pain.

By breaking down the data by age, the study revealed that adults aged 18 to 64 who had been prescribed from Gabapentine were more than twice as likely to develop dementia or MCI compared to those who had not received the drug. By decomposing it, there was no increased risk in 18 to 34 year olds to develop dementia. But for 35 to 49 year olds, the risk of dementia has more than doubled and the risk of MCI more than tripled, similar to patients aged 50 to 64.

The risks have also increased with the prescription frequency. Adults who received 12 or more prescriptions had a risk of 40% to develop dementia and 65% more likely to show the MCI compared to these less prescriptions.

Importance of current research

These results suggest that the risks of cognitive decline were more than twice as high in adults who are generally considered too young to develop these conditions.

However, researchers point out that, as it was an observation study, it cannot establish a direct cause and effect relationship. They also noted limitations, such as its retrospective design and lack of data on the gabapentine dose or the duration of processing.

Overall, they summed up in the press release: “Our results indicate an association between the prescription of Gabapentine and dementia or cognitive disorders in the 10 years. In addition, an increased frequency of prescription from Gabapentine is correlated with the impact of dementia. ”

For the moment, these results recall that pharmacology is a constantly evolving area, and even well -established treatments can reveal new effects over time, stressing the importance of research and awareness in progress.

This article does not offer medical advice and should be used for information purposes only.

Find out more: Antibiotics may not be linked to cognitive decline

Article Sources

Our writers at Discovermagazine.com Use studies evaluated by high quality peers and sources for our articles, and our publishers examine scientific precision and editorial standards. Review the sources used below for this article:

Having worked as a biomedical research assistant in laboratories in three countries, Jenny excels in translating complex scientific concepts – ranging from medical breakthroughs and pharmacological discoveries to the last nutritions – into accessible and engaging content. His interests extend to subjects such as human evolution, psychology and stories of eccentric animals. When it is not immersed in a popular scientific book, you will find it to catch waves or sail on the island of Vancouver on its longboard.